The impact of COVID-19 pandemic on technologic and process innovation in point-of-care diagnostics for sexually transmitted infections

Autor:	Yukari C. Manabe
Rok vydání:	2021
Předmět:	medicine.medical_specialty OTC over-the-counter Coronavirus disease 2019 (COVID-19) Point-of-care testing Clinical Biochemistry POC point-of-care Article AMR antimicrobial resistance WHO World Health Organization CT Chlamydia trachomatis Syndemic PCR polymerase chain reaction EUA emergency use authorization NG Neisseria gonorrhoeae Pandemic medicine diagnostics LMIC low- and middle-income countries STI sexually transmitted infection sexually transmitted infections Point of care COVID-19 coronavirus disease 2019 business.industry CLIA Clinical Laboratory Improvement Amendments Public health COVID-19 General Medicine medicine.disease FDA Food and Drug Administration point-of-care Medical emergency STI business Process innovation HIV Human Immunodeficiency Virus RADx Rapid Acceleration of Diagnostics Clearance
Zdroj:	Clinical Biochemistry
ISSN:	1873-2933
Popis:	The STI diagnostic landscape of FDA cleared tests for use at point-of-care (POC), as well as those emergency use authorized for COVID-19 are reviewed; some of these COVID-19 diagnostics may have platform potential as STI diagnostics. Finally, process innovation is described with self-collection and hub-and-spoke mail-in to reference lab models. Movement of Clinical Laboratory Improvement Amendments (CLIA)-waived POC tests to over-the-counter formats will make tests more accessible to consumers. Together with public health messaging, these measures could accelerate STI and COVID-19 syndemic diagnostic solutions.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b5332eba8aa68a80152f44523aa8b4b https://pubmed.ncbi.nlm.nih.gov/34808115 Zobrazit plný text záznamu Full Text from ScienceDirect